PSMA3 and plasma cell myeloma: Further in vivo studies confirmed that PSMA3-AS1 siRNA efficiently enhanced carfilzomib sensitivity in multiple myeloma xenografts, thereby identifying the therapeutic potential of exosomal PSMA3-AS1 from MSCs [101].